Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2025)
Monopar Therapeutics' (MNPR) quarterly Income from Continuing Operations came in at 3437601.0 in Q3 2025, down 132.97% year-on-year from 10426590.04 in Q3 2024, and down 40.11% quarter-over-quarter from 2453526.0 in Q2 2025.
Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Monopar Therapeutics has disclosed Income from Continuing Operations across 9 years of filings, most recently posting 3437601.0 for Q3 2025.
- Income from Continuing Operations for Q3 2025 came in at 3437601.0, down 132.97% year-over-year; the trailing twelve-month figure through Sep 2025 was 9991657.0 (down 47.24% YoY), and the FY2024 annual result was 15585619.0, down 85.94% from the prior year.
- Income from Continuing Operations came in at 3437601.0 for Q3 2025 at Monopar Therapeutics, down from 2453526.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1475558.0 in Q3 2024 to a low of 14050593.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 2453526.0 (2025), against an average of 2997699.94.
- Across the five-year window, Income from Continuing Operations plunged 424.06% in 2022 and jumped 35.0% in 2024, its largest moves.
- Monopar Therapeutics' Income from Continuing Operations stood at 2681118.0 in 2021, then slumped by 424.06% to 14050593.0 in 2022, then surged by 86.1% to 1953734.0 in 2023, then advanced by 24.47% to 1475558.0 in 2024, then slumped by 132.97% to 3437601.0 in 2025.
- The last three Income from Continuing Operations figures came in at 3437601.0 (Q3 2025), 2453526.0 (Q2 2025), and 2624972.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Monopar Therapeutics | 441.25 Mn | 441.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -2.45 Mn |
| Mar 31, 2025 | -2.62 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.72 Mn |
| Mar 31, 2024 | -1.64 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.33 Mn |
| Mar 31, 2023 | -2.53 Mn |
| Dec 31, 2022 | -14.05 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.76 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -2.68 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -2.26 Mn |
| Sep 30, 2020 | -1.65 Mn |
| Jun 30, 2020 | -1.46 Mn |